Additionally, further research is needed to identify reliable predictors of immune-related adverse events and to explore the potential of combining immunotherapy with novel biomarkers beyond PD-L1, such as tumor-infiltrating lymphocytes or genomic signatures, particularly in patients who show limited response to current regimens. Here, CD274 is linked to neoplasm.